Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gene therapy for muscular dystrophy].

Shin'ichi Takeda1

  • 1Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo. takeda@ncnp.go.jp

No to Hattatsu = Brain and Development
|March 23, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostaglandin E2 receptor EP2 is indispensable for maintenance of skeletal muscle stem cells.

Stem cells (Dayton, Ohio)·2026
Same author

RNA therapies are delivering as therapies for neuromuscular dystrophy patients: Editorial for the special issue on RNA therapies in Journal of Neuromuscular Diseases.

Journal of neuromuscular diseases·2025
Same author

Digital Outcome Measures for Gait and Spontaneous Locomotor Activity in Dystrophic Dogs.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.

Methods in molecular biology (Clifton, N.J.)·2025
Same journal

[Successful treatment with topiramate in a case of idiopathic intracranial hypertension refractory to acetazolamide].

No to hattatsu = Brain and development·2018
Same journal

[Clinical characteristics of early juvenile GM2 gangliosidosis: a case report].

No to hattatsu = Brain and development·2018
Same journal

[Non-invasive positive pressure ventilation during the management of severe spinal muscular atrophy type I].

No to hattatsu = Brain and development·2018
Same journal

[Ictal arterial spin labeling MRI findings in two cases of acute confusional migraine].

No to hattatsu = Brain and development·2018
Same journal

[A case of West syndrome with a deletion at chromosome 2q24.3-q31.3].

No to hattatsu = Brain and development·2018
Same journal

[Irreversible cerebral ischemia caused by febrile status epilepticus in Sturge-Weber syndrome type III].

No to hattatsu = Brain and development·2018
See all related articles

Adeno-associated virus (AAV) vector gene therapy shows promise for Duchenne muscular dystrophy (DMD). This study successfully used AAV to deliver micro-dystrophin, significantly protecting muscles in mdx mice from degeneration.

Area of Science:

  • Molecular biology
  • Genetics
  • Biochemistry

Context:

  • Duchenne muscular dystrophy (DMD) is a lethal X-linked disorder caused by dystrophin gene mutations.
  • Adeno-associated virus (AAV) vector gene transfer is a potential therapeutic approach for DMD.
  • Full-length dystrophin cDNA (14 kb) exceeds AAV vector insertion capacity (4.9 kb).

Purpose:

  • To construct and evaluate an AAV vector expressing a rod-truncated micro-dystrophin (CS1) for DMD treatment.
  • To assess the efficacy of AAV-mediated micro-dystrophin delivery in dystrophin-deficient mdx mice.

Summary:

  • AAV vector expressing micro-dystrophin CS1 under a skeletal muscle-specific MCK promoter was constructed.
  • AAV-MCK delta CS1 was injected into mdx mouse tibialis anterior (TA) muscles.

Related Experiment Videos

  • Significant expression of micro-dystrophin was observed up to 24 weeks post-injection, with reduced centrally located nuclei and improved tetanic force compared to controls.

    • Impact:

    • This study demonstrates successful protection of mdx mouse muscles from dystrophic degeneration using AAV-delivered micro-dystrophin.
    • The findings support the potential of AAV-based gene therapy for DMD by delivering functional micro-dystrophin.
    • This approach offers a viable strategy to overcome the size limitations of AAV vectors for treating genetic muscle disorders.